These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 17059382)
1. Tolcapone in the management of Parkinson's disease. Leegwater-Kim J; Waters C Expert Opin Pharmacother; 2006 Nov; 7(16):2263-70. PubMed ID: 17059382 [TBL] [Abstract][Full Text] [Related]
2. Tolcapone: a review of its use in the management of Parkinson's disease. Keating GM; Lyseng-Williamson KA CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329 [TBL] [Abstract][Full Text] [Related]
3. Role of tolcapone in the treatment of Parkinson's disease. Leegwater-Kim J; Waters C Expert Rev Neurother; 2007 Dec; 7(12):1649-57. PubMed ID: 18052761 [TBL] [Abstract][Full Text] [Related]
4. Utility of tolcapone in fluctuating Parkinson's disease. Stocchi F; De Pandis MF Clin Interv Aging; 2006; 1(4):317-25. PubMed ID: 18046910 [TBL] [Abstract][Full Text] [Related]
5. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Borges N Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899 [TBL] [Abstract][Full Text] [Related]
6. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease. Limousin P; Pollak P; Gervason-Tournier CL; Hommel M; Perret JE Lancet; 1993 Jun; 341(8860):1605. PubMed ID: 8099689 [No Abstract] [Full Text] [Related]
7. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Deane KH; Spieker S; Clarke CE Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539 [TBL] [Abstract][Full Text] [Related]
9. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084 [TBL] [Abstract][Full Text] [Related]
10. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K; Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133 [TBL] [Abstract][Full Text] [Related]
11. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498 [TBL] [Abstract][Full Text] [Related]
12. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Guay DR Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075 [TBL] [Abstract][Full Text] [Related]
13. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Benabou R; Waters C Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105 [TBL] [Abstract][Full Text] [Related]
14. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116 [TBL] [Abstract][Full Text] [Related]
15. COMT inhibition in the treatment of Parkinson's disease. Ruottinen HM; Rinne UK J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337 [TBL] [Abstract][Full Text] [Related]
16. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis. Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736 [TBL] [Abstract][Full Text] [Related]